Yiheng Capital Management Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Roblox
RBLX
|
+$38.5M |
| 2 |
Keros Therapeutics
KROS
|
+$28M |
| 3 |
indie Semiconductor
INDI
|
+$21.1M |
| 4 |
Viridian Therapeutics
VRDN
|
+$8.51M |
| 5 |
JD.com
JD
|
+$5.75M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
+$32.2M |
| 2 |
HIMX
Himax Technologies
HIMX
|
+$30.4M |
| 3 |
New Oriental
EDU
|
+$20.2M |
| 4 |
AKRO
Akero Therapeutics
AKRO
|
+$15.3M |
| 5 |
TransDigm Group
TDG
|
+$4.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Communication Services | 12.45% |
| 2 | Consumer Discretionary | 9.02% |
| 3 | Healthcare | 8.08% |
| 4 | Consumer Staples | 5.97% |
| 5 | Industrials | 5.67% |
Similar funds
Yiheng Capital Management's Q1 2023 Portfolio in Review
As of Q1 2023, Yiheng Capital Management held 37 positions worth $2.53B, up 12% from $2.26B the previous quarter. Its ten largest holdings account for 83% of the portfolio.
Yiheng Capital Management deployed $482M of net new capital in Q1 2023, opening 4 new positions and adding to 7 existing holdings. Its largest new stake was Roblox: 1,008,274 shares worth $45.4M.
By sector, the portfolio is most concentrated in Communication Services at 12% of assets, up from 12% a quarter earlier, followed by Consumer Discretionary and Healthcare.
On the sell side, the largest reduction was IVERIC bio, Inc. Common Stock, an estimated $32.2M trimmed.
- Yiheng Capital Management's largest Q1 2023 buy was Roblox: 1,008,274 shares worth $45.4M.
- Yiheng Capital Management added most to Viridian Therapeutics in Q1 2023, an estimated $8.51M increase.
- Yiheng Capital Management's biggest Q1 2023 reduction was IVERIC bio, Inc. Common Stock, cutting an estimated $32.2M.
- Yiheng Capital Management's ten largest holdings make up 83% of its $2.53B portfolio in Q1 2023.
- Yiheng Capital Management opened 4 new positions and closed 2 in Q1 2023.
- Yiheng Capital Management's portfolio value rose 12% quarter-over-quarter to $2.53B.
Based on Yiheng Capital Management's 13F filing for Q1 2023, filed 15 May 2023.